Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex

Annals of Clinical Psychiatry

Volumn 23, Issue 4, 2011, Pages 263-269

  Chung, Thomas K ^a   Lynch, Elizabeth R ^a   Fiser, Cheryl J ^a   Nelson, Daniel A ^a   Agricola, Karen ^a   Tudor, Cynthia ^a   Franz, David Neal ^a   Krueger, Darcy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Behavior; Psychiatric comorbidities; Treatment; Tuberous sclerosis complex

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; DEXMETHYLPHENIDATE; ESCITALOPRAM; ETIRACETAM; GABAPENTIN; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; METIROSINE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; PSYCHOTROPIC AGENT;

ADJUSTMENT DISORDER; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; COGNITION; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG USE; DSM-IV-TR; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SYMPTOM; THOUGHT DISORDER; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANXIETY DISORDERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 84858302207     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10:299-313.
2. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol. 2002;6:15-23. (Pubitemid 34436477)
3. Muzykewicz DA, Newberry P, Danforth N, et al. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav. 2007;11:506-513. (Pubitemid 350177384)
4. de Vries P, Humphrey A, McCartney D, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in tuberous sclerosis. Eur Child Adolesc Psychiatry. 2005;14:183-190.
5. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13:624-628. (Pubitemid 29035481)
6. Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
7. Prather P, de Vries PJ. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol. 2004;19:666-674. (Pubitemid 39530075)
8. Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68:64-80. (Pubitemid 32048362)
9. Jones AC, Shyamsundar MM, Thomas MW, et al. Comprehensive mutation analysis of TSC1 and TSC2- and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999;64:1305-1315. (Pubitemid 30468748)
10. Sancak O, Nellist M, Goedbloed M, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype - phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13:731-741. (Pubitemid 40846845)
11. McElroy SL, Keck PE Jr, Post RM, eds. Antiepileptic drugs to treat psychiatric disorders. New York, NY: Informa Healthcare; 2008.
12. Ehninger D, de Vries PJ, Silva AJ. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res. 2009;53:838-851.
13. Hunt A, Shepherd C. A prevalence study of autism in tuberous sclerosis. J Autism Dev Disord. 1993;23:323-339.
14. Smalley SL, Tanguay PE, Smith M, et al. Autism and tuberous sclerosis. J Autism Dev Disord. 1992;22:339-355.
15. Kopp CM, Muzykewicz DA, Staley BA, et al. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav. 2008; 13:505-510.
16. Lewis JC, Thomas HV, Murphy KC, et al. Genotype and psychological phenotype in tuberous sclerosis. J Med Genet. 2004;41:203-207. (Pubitemid 38333799)
17. Pulsifer MB, Winterkorn EB, Thiele EA. Psychological profile of adults with tuberous sclerosis complex. Epilepsy Behav. 2007;10:402-406. (Pubitemid 46567778)
18. Raznahan A, Joinson C, O'Callaghan F, et al. Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis. J Intellect Disabil Res. 2006; 50:561-569. (Pubitemid 44027277)
19. Staley BA, Montenegro MA, Major P, et al. Selfinjurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients. Epilepsy Behav. 2008;13:650-653.
20. Ess KC. The neurobiology of tuberous sclerosis complex. Semin Pediatr Neurol. 2006;13:37-42. (Pubitemid 43963399)
21. Jaworski J, Sheng M. The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol. 2006;34:205-219.